Engflag

Mucodox

Quick links to important sections

Mucodox

Selected form

Mucodox_DE

Method of action: Cough And Cold Preparations

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mucodox

What is Mucodox? Sobrerol Overview

Property Description
Active ingredient Sobrerol
Form Tablets, Syrup, Granules, Solutions (Nebulization/Injection)
Pharmacological class Mucolytic Agent
Common use Facilitating respiratory clearance of thick mucus
Origin Synthetic Monoterpenoid

What is Mucodox and What Type of Medicine is Sobrerol?

Mucodox is a pharmaceutical preparation whose active ingredient is Sobrerol, primarily classified as a mucolytic agent. This means it belongs to the group of muco-active drugs used specifically to modify the properties of respiratory secretions. Sobrerol is a single-ingredient, synthetic compound derived from the monoterpenoid chemical family. Its official designation places it within the mucolytic subgroup; for instance, it is recognized under the official R05CB07 code. Unlike traditional expectorants, Sobrerol is distinguished by its direct chemical intervention on the mucus structure, a process utilized in conditions marked by excessively viscous phlegm.

Composition and Available Forms of Mucodox

The core component of this medicine is the active substance Sobrerol (C10H18O2), which is formulated with excipients suitable for different delivery methods. Sobrerol is commonly available in multiple presentation types to suit patient needs and clinical scenarios, including standard oral forms such as tablets and specialized syrup preparations, as well as granules in water-soluble sachets. Crucially, solutions specifically formulated for delivery via nebulization are manufactured, offering a route for localized, targeted action directly within the respiratory passages.

General Purpose: How Mucodox Aids Respiratory Clearance

The general therapeutic purpose of a mucolytic agent like Sobrerol is to promote the easy expectoration of thick, tenacious mucus, thereby aiding the body's effort to clear the airways. The drug achieves this by chemically reducing the viscosity and elasticity of the accumulated secretions. Sobrerol acts on the mucus structure to increase the production of less viscous mucus, leading to improved clearance. This action helps the phlegm become easier to move and cough up, which assists in relieving congestion. By targeting the molecular bonds within the mucin structures, the drug functions to enhance the efficiency of the mucociliary clearance process.

What side effects are possible with Mucodox?

Possible Side Effects and Safety Information

The information presented here details the officially documented adverse reactions and safety constraints of Mucodox (Sobrerol), strictly based on governmental regulatory sources. The safety profile is defined by specific precautions and contraindications, rather than a broad spectrum of common side effects.

Adverse Reaction Scope

The primary adverse event documented in regulatory texts is the potential for hypersensitivity reactions to the active substance, Sobrerol, or to the product's excipients. This reaction is classified under Immune System Disorders. Official regulatory classifications do not consistently define a specific frequency category (such as common or uncommon) for this reaction.

Official Safety Constraints and Precautions

Official labeling sets forth specific limitations on the use of Mucodox:

  • Contraindications: Use is formally prohibited in cases of known hypersensitivity to the active substance or any of the inactive ingredients. It is also contraindicated in children generally younger than 2 years of age (for specific forms) and in patients with phenylketonuria (PKU) if the specific formulation contains aspartame.

  • Required Caution: Regulatory documents specify that particular caution must be exercised when the medicine is used by individuals with severe respiratory insufficiency, asthmatic patients, or those who are generally debilitated. This caution relates to the drug's action of fluidifying mucus, which necessitates an effective ability to clear the respiratory secretions.

Safety Profile Summary

The regulatory safety profile is structured to restrict the medicine's use in vulnerable populations and those with pre-existing conditions that might be complicated by the pharmacological effect. Safety is primarily managed through these specific contraindications and cautions, rather than through monitoring for a wide range of frequently occurring adverse effects.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The official regulatory profile for Mucodox (Sobrerol) is defined by its low toxicological risk and the mandatory requirements for general supportive care. The active substance, Sobrerol, is generally associated with very low acute toxicity and high tolerability according to toxicological findings supporting its authorization.

Specific severe, dose-dependent clinical signs of overdose, such as cardiovascular or neurological events, are not detailed in publicly accessible government regulatory summaries. Consequently, no specific life-threatening complications are explicitly cited as a direct outcome of overdose in the official labeling.

Overdose Context Regulatory Mandates
Documented Toxicity Low acute toxicity; specific severe symptoms not detailed.
Antidote Availability No specific antidote is known or documented in official labeling.
Management Measure Treatment is limited to symptomatic and supportive care.

Emergency Actions Required

Immediate medical attention must be sought if any suspected overdose is known or has occurred, even in the absence of initial severe symptoms. This is mandated by regulatory agencies to ensure professional assessment. Emergency services must be contacted immediately if the affected individual experiences difficulty breathing, collapses, or cannot be awakened. Management in a medical setting involves the continuous monitoring of vital signs and providing the necessary supportive measures as determined by the patient's condition.

Therapeutic Uses of Mucodox

What Mucodox Treats: Main Uses and Benefits

Mucodox (Sobrerol) is commonly used to help with symptoms related to physical discomfort caused by the presence of excessively viscous phlegm or thick, sticky sputum. Pharmacologically, the active ingredient in Mucodox is a mucolytic agent. It is applied in addressing conditions marked by mucus hypersecretion, which can create noticeable physiological strain and hinder the body's natural clearance. This agent is relevant for easing symptoms during acute respiratory tract infections (RTIs), in long-term afflictions such as chronic bronchitis, and in related hypersecretory bronchopulmonary diseases. The key therapeutic benefit contributes to easing the overall symptom load by fluidifying the mucus, and contributes to easing the process of expectoration.

Quick Fact: Relief for Thick, Tenacious Sputum

Symptomatic management is the focus for this therapeutic use. The medication is commonly used when symptoms cluster into patterns requiring supportive management, such as a persistent cough with difficult expectoration and the sensation of congestion. This approach is applied across domains where additional symptomatic support is needed to facilitate airway clearance and helps patients cope more steadily with symptom fluctuations.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Mucodox (methotrexate) is strictly authorized for specific oncological uses, including the treatment of acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma in adult and pediatric patients. It is not indicated for non-oncology diseases when formulated for high-dose use.

Contraindicated Populations

Regulatory agencies formally prohibit the use of this medicine in the following groups:

  • Pregnant females: The medicine is contraindicated due to the high risk of embryo-fetal toxicity, including fetal death and severe congenital abnormalities.
  • Hypersensitivity: Individuals with a history of severe hypersensitivity reactions to methotrexate, including anaphylaxis, must not use this medicine.

Use Restrictions and Special Considerations

The use of Mucodox is restricted or requires special medical consideration in several populations to prevent toxicity:

  • Renal Impairment: Patients with reduced kidney function may require a dose reduction or discontinuation as the drug is primarily cleared through the kidneys.
  • Lymphoproliferative Disease: The drug must be discontinued if this condition develops.
  • Reproductive Potential: Both females and males of reproductive potential must use effective contraception during treatment and for a specified period after the final dose due to the risk of reproductive toxicity and birth defects.
  • Live Vaccines: Use of live vaccines is generally not recommended during treatment due to the risk of disseminated infection and reduced vaccine effectiveness.

This medicine's eligibility profile is primarily defined by the need to exclude all risk of exposure during pregnancy and in patients with a history of severe allergic reactions, while requiring careful management in those with impaired organ function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Type Official Regulatory Status
Drug–Drug Interactions (DDI) No known interactions. The active substance Sobrerol is documented in regulatory summaries as having no known interactions with other medicinal products, including no specific pharmacokinetic or pharmacodynamic conflicts.
Metabolic/Transporter None documented. Official prescribing information does not list enzyme-mediated interactions involving CYP enzymes or drug transport proteins.

The formal interaction profile for Mucodox primarily focuses on substance- and excipient-based restrictions rather than traditional drug-drug interactions. These constraints are documented in regulatory labeling to manage specific risks related to the product's formulation.

Key Substance- and Population-Specific Restrictions

  • Alcohol (Ethanol) Content: The liquid (syrup) formulation contains ethyl alcohol. Regulatory documents mandate this be noted as harmful for those suffering from alcoholism. Furthermore, the alcohol content must be strictly considered for patients with pre-existing conditions, including liver disease or epilepsy.
  • Excipient-Based Restrictions: Specific formulations are restricted based on the presence of non-active ingredients. Products containing sucrose or sorbitol are subject to warnings for patients with rare hereditary metabolic issues, such as hereditary fructose intolerance, glucose/galactose malabsorption, and sucrase/isomaltase insufficiency. Formulations that include aspartame are restricted for individuals diagnosed with phenylketonuria.

Mechanism of Action

Mechanism of Action: How Mucodox Works

Mucodox is administered as an inactive prodrug that requires rapid hepatic conversion to its active metabolite, Met-I, to be effective. This required metabolic activation ensures the systemic delivery of the functional molecule to the respiratory tract.

The mechanism of action is dual. First, Met-I acts as a mucolytic agent by cleaving the disulfide bonds that cross-link the polymeric mucin glycoproteins. This direct chemical action reduces the viscosity and elasticity of bronchial secretions, thereby facilitating mucociliary transport and the expulsion of secretions.

Second, the free sulfhydryl groups on Met-I function as antioxidants and free radical scavengers. By neutralizing Reactive Oxygen Species (ROS), this activity modulates the redox state of the airway epithelium, thereby influencing local oxidative stress within the respiratory system.

Dosage and Administration Information

Mucodox, which contains the active substance Sobrerol, is associated with specific parameters regarding routes, frequency, and duration of use. This information describes the administration framework of the medication without addressing its therapeutic effects or safety profile.

Administration Routes and Forms

The medicine is available for several methods of delivery. These include oral administration (such as syrup or granules), inhalation via nebulized solution, intramuscular injection, and rectal delivery via suppository.

Official Dosing and Schedule

Adults: The standard regimen for oral forms is a total daily dose of 600 mg, typically delivered as two 300 mg units. For most forms, the frequency pattern is twice daily (b.i.d.). Intramuscular administration is dosed at 60 mg to 120 mg per day. The duration of treatment for acute conditions is defined such that it must not exceed 3 consecutive days.

Contextual and Age-Specific Rules

Preparation: The oral granules must be fully dissolved in half a glass of water before ingestion.

Pediatric Use: Use is indicated for children over 30 months of age. Because the oral syrup formulation contains ethanol, alternative forms are recommended for children under 6 years of age.

Connection to the Overall Use Protocol

The use protocol for Sobrerol is characterized by four delivery routes and a time constraint that limits administration to a maximum of three days. This framework standardizes the dosage at 600 mg per day for adults and includes preparation steps for specific forms, ensuring a consistent application of the medicine.

Recent Clinical Evidence

Mucodox: Recent Clinical Evidence

Clinical evidence for Mucodox, which typically contains the active substance erdosteine, has focused primarily on its effectiveness in treating respiratory conditions characterized by excessive mucus production, such as Chronic Obstructive Pulmonary Disease (COPD) and acute exacerbations of chronic bronchitis.

Erdosteine is categorized as a thiol-based mucolytic agent. It functions not only by breaking down the chemical bonds in mucus to make it less viscous (mucolytic action) but also exhibits antioxidant and anti-inflammatory properties, which are often cited as contributing to its overall benefit in chronic lung diseases.

Efficacy and Reduced Exacerbations

Clinical trials have investigated the impact of long-term erdosteine therapy on disease progression and acute episodes. Studies, including a landmark trial on frequent COPD exacerbators, found that adding erdosteine to standard therapy significantly reduced the risk of acute exacerbations of COPD (AECOPDs), shortened their duration, and decreased the rate of hospitalization compared to placebo.

Additionally, research suggests that erdosteine can enhance the penetration of certain antibiotics (e.g., amoxicillin) into respiratory secretions, potentially improving the efficacy of antibiotic treatment during infective exacerbations of chronic bronchitis, leading to faster symptom relief.

Symptom Management and Safety Profile

In studies comparing erdosteine to other mucoactive drugs (like ambroxol), erdosteine 300 mg taken twice daily demonstrated a quicker and more effective reduction in the frequency and severity of cough and sputum viscosity. It has been generally well-tolerated in clinical settings, with a low reported incidence of adverse events. The most commonly noted side effects are mild and transient gastrointestinal disturbances, such as nausea or diarrhea.

Note: While some formulations of Mucodox may contain other mucoactive agents like sobrerol or doxophylline, the most robust clinical evidence for the product name is associated with the active ingredient erdosteine in the context of chronic respiratory disease management.

Frequently Asked Questions (FAQ)

Common questions about Mucodox (FAQ)

Q: What should I do if I miss a dose of Mucodox?

Product labels generally state that if a dose is missed, patients should consider taking it as soon as they remember. However, if it is almost time for the next scheduled dose, regulatory guidelines indicate the missed dose is typically skipped. The official labeling specifies that a patient should not take a double dose to compensate for a missed one.

Q: What are the signs of an overdose and what should I do if I take too much?

Regulatory documents detail the anticipated signs and symptoms of a drug overdose, which are often based on clinical trials of high exposure. If an overdose is suspected, official information directs patients to seek immediate medical attention by contacting a physician, emergency services, or a poison control center. Regulatory sections also describe the general medical management necessary in such an event.

Q: Is it safe to drive or operate machinery after taking this medicine?

Official prescribing information addresses the potential impact of Mucodox on a person’s ability to drive and use machines. If the medicine is known to be associated with central nervous system effects such as dizziness, confusion, or somnolence (feeling very sleepy), regulatory bodies advise caution. If such effects occur, patients are advised in the product information to avoid driving or operating machinery.

Q: What are the common side effects of Mucodox?

The official Adverse Reactions section of the regulatory label lists all known side effects and provides their estimated frequency, noting which ones are considered 'common' based on clinical trial data. This statistical information on common side effects is contained within the official product labeling and should be reviewed by a healthcare provider.

How should Mucodox be stored and disposed of?

How to Store and Dispose of Mucodox?

This section outlines the official, regulatory requirements for the storage, handling, and disposal of Mucodox (Sobrerol).

Requirement Category Official Storage and Handling Rules
Temperature and Environment Must be kept away from excessive heat; specific forms (e.g., suppositories) should not exceed 30 C. The medicine must be protected from moisture and stored away from direct light.
Container Integrity The container must be kept securely sealed when not in use to protect the product. Do not use the medicine after the expiration date printed on the package.
Handling and Protection Keep out of the sight and reach of children as a mandatory safety requirement. Store the product away from incompatible materials.
Disposal Instructions Unused or expired Mucodox must be disposed of in accordance with official local or national regulations. Avoid flushing the product down drains or releasing it into waterways to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagPortugal

Equivalent of Mucodox found in:

A-Z Index: